BioCentury
ARTICLE | Financial News

Cullinan raises $150M in series A

October 6, 2017 7:21 PM UTC

On Oct. 3, Cullinan Oncology LLC (Cambridge, Mass.) raised $150 million in a series A round led by the UBS Oncology Impact Fund -- which is managed by MPM Capital -- and F2 Ventures. MPM created Cullinan to both in-license cancer assets and discover and develop its own internal oncology pipeline.

MPM’s Owen Hughes, who is CEO of the newco, told BioCentury the company has already in-licensed one undisclosed program and has two other undisclosed internal programs in development. Hughes was CBO and head of corporate development at drug delivery company Intarcia Therapeutics Inc. (Boston, Mass.)...

BCIQ Company Profiles

Cullinan Oncology Inc.